Finally, to test the clinical relevance of our datasets for chronic p53 targets, we performed recursive partitioning analysis (RPA) of each Rcade component for survival in four publicly available cancer datasets (Fig. 5A) [31–33]. This evidence concerns the gene TP53 and cancer.